DGAP-News: STADA acquires British branded product Cetraben(R) for GBP 30 million (approx. EUR 34.6 million)
(firmenpresse) - DGAP-News: STADA Arzneimittel AG / Key word(s): Mergers&Acquisitions
STADA acquires British branded product Cetraben(R) for GBP 30 million
(approx. EUR 34.6 million)
26.05.2011 / 11:50
---------------------------------------------------------------------
Bad Vilbel, May 26, 2011 - STADA Arzneimittel AG, has today, on May 26,
2011, signed the contracts for the purchase of the British branded product
Cetraben(R). The sellers are various companies and a private individual.
The purchase price amounts to GBP 30 million (approx. EUR 34.6 million).
STADA will use cash on hand to finance the acquisition.
Since 2006, the British STADA subsidiary Genus Pharmaceuticals has sold,
under the Cetraben(R) brand, a moisturizing cream and bath essence in the
therapeutic area of dermatology for the treatment of skin eczema and dry
skin as a licensed product in the UK. On completion of the purchase
contractually agreed today, these previously in-licensed products will be
transferred to the ownership of Genus Pharmaceuticals. In 2010, Genus
Pharmaceuticals generated sales of GBP 7.5 million (approx. EUR 8.7
million) with these high-margin and seasonally independent products and
thus achieved sales growth of 27% compared to 2009.
Between 2006 and 2010, Genus Pharmaceuticals generated average annual
growth rates of 30% with these products. After the purchase, the Company,
from today's perspective, also sees good chances of maintaining this strong
growth at a similar level. The planned introduction of further products
under the Cetraben(R) brand name is also expected to contribute to this.
The acquisition of the Cetraben(R) branded products secures both products,
whose license agreement would have expired at the end of 2012, for the
product portfolio of Genus Pharmaceuticals in the long term; in addition,
the profitability of Genus Pharmaceuticals will be considerably improved as
a result of the license payments previously in the amount of 15% of net
sales, which will no longer be applicable in the future.
In the context of the acquisition, STADA has acquired the brands, the
approvals, the product pipeline and the domain names for Europe and a large
number of Eastern European countries including Russia as well as joint
ownership of the dossier. The STADA Group therefore also has the
opportunity to internationalize the Cetraben(R) products and thus develop
additional growth impulses for both products. Furthermore, the acquisition
will allow STADA to further expand its expertise in the area of
dermatology.
Additional information:
STADA Arzneimittel AG / Corporate Communications / Stadastraße 2-18 / D -
61118 Bad Vilbel /
Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-506 / E-mail:
communications(at)stada.de
Or visit us in the Internet at www.stada.com.
End of Corporate News
---------------------------------------------------------------------
26.05.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel
Deutschland
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications(at)stada.de
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Listed: Regulierter Markt in Düsseldorf, Frankfurt (Prime
Standard); Freiverkehr in Berlin, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
126309 26.05.2011
Datum: 26.05.2011 - 11:50 Uhr
Sprache: Deutsch
News-ID 34224
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 322 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: STADA acquires British branded product Cetraben(R) for GBP 30 million (approx. EUR 34.6 million)"
steht unter der journalistisch-redaktionellen Verantwortung von
STADA Arzneimittel AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
